Genetic Diseases:?It’s a disease that often strikes people in the prime of life, slowly destroying control over body, mind and personality. It inevitably kills the patient, but usually only after at least a decade of suffering. The underlying cause of Huntington’s disease – a dominant mutation on Chromosome IV – was discovered almost 25 years ago. Now the first trials to target the condition at its source have begun. Chances of finding a cure have never been more realistic.
BIO-Europe more popular than ever
Latest NewsMore than 4,000 participants from all over the globe visited Berlin in early November to take part in this year’s BIO-Europe. The event continues to be on the upswing – like the biotech industry itself.
Spain pushes circular bioeconomy
Latest NewsConversion of agricultural waste into useful products is a worldwide need. As part of the European Project Valor Plus, Spanish biotechindustry association ASEBIO invited its members to visit the recently opened second-generation biorefinery Clamber.
Stem cells cure deadly human skin disease
Latest NewsFor the first time researchers at universities Bochum (Germany), Salzburg (Austria), and Modena (Italy) have shown that autologous transgenic keratinocyte cultures can regenerate an entire, fully functional epidermis on a seven-year-old child suffering from junctional epidermolysis bullosa (JEB).
InflaRx Announces Pricing of Initial Public Offering
Latest NewsGerman inflammation and autoimmunity specialist InflaRx AG (Jena) announced it will offer 6,667,000 common shares at an Nasdaq initial public offering price of $15.00 per common share, resulting in total gross proceeds of approximately US$100m.
FDA lifts clinical hold on Cellectis Phase I trials
Latest NewsThe US Food and Drug Administration (FDA) has lifted the clinical hold due to a patient death on Phase I testing of UCART123 in acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN).
The hunt for a cure for Huntington’s
BackgroundGenetic Diseases:?It’s a disease that often strikes people in the prime of life, slowly destroying control over body, mind and personality. It inevitably kills the patient, but usually only after at least a decade of suffering. The underlying cause of Huntington’s disease – a dominant mutation on Chromosome IV – was discovered almost 25 years ago. Now the first trials to target the condition at its source have begun. Chances of finding a cure have never been more realistic.
MAB Discovery expands 2013 partnership with BioNTech AG
Latest NewsGerman MAB Discovery GmbH has extended its 2013 collaboration with BioNTech AG by a contract to produce another set of therapeutic antibodies against a range of targets delivered by BioNTec.
European biotech stocks: New wave of optimism
Latest NewsNousCom raises €42m
Latest NewsSwiss oncolytic virus and vaccine specialist NousCom has closed a €42m Series B financing round led by new investor Abingworth. Co-investors include new 5AM Ventures, and existing investors LSP and Versant Ventures.
Designed for sampling.
ProductsAseptic Sample Transfer out of a Closed, Sterile System: due to the Sterisart® Septum Technology.